Andersons pediatric cardiology 1679
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.71 KB, 3 trang )
flutter.BrHeartJ.1980;44(5):602–603.
254.KirklinJW,EllisFHJr.Surgicalreliefofdiffuse
subvalvularaorticstenosis.Circulation.
1961;24:739–742.
255.AltarabshehSE,DearaniJA,BurkhartHM,etal.
Outcomeofseptalmyectomyforobstructive
hypertrophiccardiomyopathyinchildrenand
youngadults.AnnThoracSurg.
2013;95(2):663–669[discussion669].
256.MaronBJ,NishimuraRA,McKennaWJ,etal.
Assessmentofpermanentdual-chamberpacing
asatreatmentfordrug-refractorysymptomatic
patientswithobstructivehypertrophic
cardiomyopathy.Arandomized,double-blind,
crossoverstudy(M-PATHY).Circulation.
1999;99(22):2927–2933.
257.NishimuraRA,TrustyJM,HayesDL,etal.
Dual-chamberpacingforhypertrophic
cardiomyopathy:arandomized,double-blind,
crossovertrial.JAmCollCardiol.
1997;29(2):435–441.
258.MaronBJ,NishimuraRA.Surgicalseptal
myectomyversusalcoholseptalablation:
assessingthestatusofthecontroversyin2014.
Circulation.2014;130(18):1617–1624.
259.MaronBJ,ShenWK,LinkMS,etal.Efficacyof
implantablecardioverter-defibrillatorsforthe
preventionofsuddendeathinpatientswith
hypertrophiccardiomyopathy.NEnglJMed.
2000;342(6):365–373.
260.MaronBJ,MaronMS,SemsarianC.Doubleor
compoundsarcomeremutationsinhypertrophic
cardiomyopathy:apotentiallinktosuddendeath
intheabsenceofconventionalriskfactors.
HeartRhythm.2012;9(1):57–63.
261.RowinEJ,MaronBJ,HaasTS,etal.
Hypertrophiccardiomyopathywithleft
ventricularapicalaneurysm:implicationsfor
riskstratificationandmanagement.JAmColl
Cardiol.2017;69(7):761–773.
262.MaronBJ,CaseySA,ChanRH,etal.
IndependentassessmentoftheEuropeansociety
ofcardiologysuddendeathriskmodelfor
hypertrophiccardiomyopathy.AmJCardiol.
2015;116(5):757–764.
263.LambiasePD,GoldMR,HoodM,etal.
EvaluationofsubcutaneousICDearly
performanceinhypertrophiccardiomyopathy
fromthepooledEFFORTLESSandIDE
cohorts.HeartRhythm.2016;13(5):1066–1074.
264.AxelssonA,IversenK,VejlstrupN,etal.
EfficacyandsafetyoftheangiotensinIIreceptor
blockerlosartanforhypertrophic
cardiomyopathy:theINHERITrandomised,
double-blind,placebo-controlledtrial.Lancet
DiabetesEndocrinol.2015;3(2):123–131.
265.SaberiS,WheelerM,Bragg-GreshamJ,etal.
EffectofModerate-intensityexercisetrainingon
peakoxygenconsumptioninpatientswith
hypertrophiccardiomyopathy:Arandomized
clinicaltrial.JAMA.2017;317(13):1349–1357.
266.TowbinJA,LoweAM,ColanSD,etal.
Incidence,causes,andoutcomesofdilated
cardiomyopathyinchildren.JAMA.
2006;296(15):1867–1876.
267.NugentAW,DaubeneyPE,ChondrosP,etal.
Theepidemiologyofchildhoodcardiomyopathy
inAustralia.NEnglJMed.2003;348(17):1639–
1646.
268.LipshultzSE,SleeperLA,TowbinJA,etal.The
incidenceofpediatriccardiomyopathyintwo
regionsoftheUnitedStates.NEnglJMed.
2003;348(17):1647–1655.
269.ArolaA,JokinenE,RuuskanenO,etal.
Epidemiologyofidiopathiccardiomyopathiesin
childrenandadolescents.Anationwidestudyin
Finland.AmJEpidemiol.1997;146(5):385–393.
270.AndrewsRE,FentonMJ,RidoutDA,BurchM.
BritishcongenitalcardiacA.New-onsetheart
failureduetoheartmusclediseaseinchildhood:
aprospectivestudyintheUnitedkingdomand
